MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline ...

Presenting at the annual J.P. Morgan Healthcare Conference on Monday, Moderna said it expects 2025 revenue of roughly $1.9 ...

Moderna is up 20% YTD, with a golden cross suggesting a trend reversal. Momentum indicators make it a top 2026 pick.

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

We recently published 10 Stocks Jim Cramer Talked About . Moderna Inc. (NASDAQ:MRNA) is one of the stocks on Jim Cramer ...

Moderna Inc. (NASDAQ: MRNA) is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. This might not be enough to turn around the fortunes of the developer of go-to COVID-19 ...

At the 44 th Annual JP Morgan Healthcare Conference on Monday, Moderna Inc. (NASDAQ:MRNA) said that it expects to report ...

Moderna reiterated its plan to deliver up to 10% revenue growth in 2026 while further reducing operating expenses. The ...

Moderna will release its fourth-quarter earnings soon, and analysts anticipate a low double-digit loss decline.